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ABSTRACT
Background: Candida species are responsible
for 15% of bloodstream infections, leading to
prolonged hospitalizations and increased mor-
tality. With the rise in obesity, antifungal dos-
ing is unclear. The purpose of this study was to
determine differences in clinical outcomes
between obese versus non-obese patients with
Candida bloodstream infections.
Methods: This retrospective cohort included
adult patient’s first episode of Candida blood-
stream infection treated with C 48 h of anti-
fungal therapy between 1 June 2013 and 31
August 2019. Patients were excluded for: dual
systemic antifungal therapy, polymicrobial
infections, or chronic candidiasis. The primary
outcome was infection-related length of stay.
Secondary outcomes included: time to can-
didemia resolution, 30-day readmission rates,
and in-hospital mortality.
Results: Eighty patients were included (28
obese; 52 non-obese). Most were male (55%);
median age was 54 years. Median BMI and
weight were 36.3 kg/m2 and 103 kg versus
20.4 kg/m2 and 61 kg, respectively (p\0.01).
Baseline characteristics were comparable. C.
albicans was isolated in 37.5% of cultures and C.
glabrata in 30%. Micafungin was utilized
empirically in 72.5% of patients; obese patients
received definitive micafungin more frequently
(57.1% vs. 21.2%; p\0.01) and were treated
longer (13 versus 10 days; p = 0.04). Infection-
related length of stay was 19 days in the obese
patients and 13 days in the non-obese patients
(p = 0.05). Non-obese patients had a shorter
duration of candidemia (5 versus 6 days;
p = 0.02). In-hospital mortality was numerically
higher in obese patients (21.4% versus 13.5%;
p = 0.36). There were no differences in 30-day
readmissions between groups.
Conclusions: Worse clinical outcomes were
observed for obese versus non-obese patients.
Further clinical research is warranted.
Keywords: Candida; Fluconazole; Fungemia;
Micafungin; Obesity
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Key Summary Points
Rates of both candidemia and obesity are
increasing.
Pharmacokinetics of standard of care
therapy, including fluconazole and
echinocandins, are altered in obese
patients though clinical correlation has
not been established.
In this study, obese patients with
candidemia displayed worse clinical
outcomes (infection-related length of stay
and duration of candidemia).
INTRODUCTION
In a nationwide surveillance study conducted
from 2011 to 2014, three Candida species were
listed in the top 15 causative organisms of
nosocomial infections [1]. Candida albicans and
C. glabrata represent the 6th and 11th leading
causes of central line-associated bloodstream
infections. Candida species cause nearly 15% of
all bloodstream infections in hospitalized
patients and contribute to prolonged hospital-
izations, increased cost, and increased morbid-
ity and mortality [1, 2]. Mortality rates up to
nearly 50% have been attributed to nosocomial
candidemia with increased risk associated with
delay of adequate antifungal therapy [3, 4].
According to the Centers for Disease Control
and Prevention, approximately 40% of adults in
the USA are obese; the rate of obesity has been
gradually increasing over time [5, 6]. Although
fluconazole and the echinocandins are the
drugs of choice for the treatment of Candida
infections, pharmacokinetic studies have
demonstrated that target attainment is
unachievable utilizing standard dosing strate-
gies of these agents in obese patients [7–11].
Additionally, clinical efficacy has not been
established in this patient population. There-
fore, the purpose of this study was to determine
if a difference in clinical outcomes exists
between obese and non-obese patients with
Candida bloodstream infections.
METHODOLOGY
Study Design, Setting, and Patient
Population
A retrospective cohort study of Candida blood-
stream infections was conducted at an academic
medical center and tertiary referral center. Adult
patients who received C 48 h of antifungal
therapy between 1 June 2013 and 31 August
2019 with a positive blood culture for Candida
were included. Eligible patients were identified
utilizing TheraDoc Clinical Surveillance (Pre-
mier, Inc., 2018). Patients were divided into two
groups: obese and non-obese. Patients were
excluded if they received combination antifun-
gal therapy, had polymicrobial infections, or
had chronic candidiasis. If a patient had mul-
tiple courses of candidemia, only the first epi-
sode was included in the analysis. The
presented study received approval from The
University of Mississippi Office of Research
Integrity Institutional Review Board and con-
formed to the Helsinki Declaration of 1964 (as
revised in 2013) concerning human and animal
rights. Since the investigation was carried out
through retrospective review of medical records,
ethics approval was not required because of no
foreseeable impact on the rights and/or welfare
of subjects involved. Consent from study par-
ticipants was additionally not obtained because
the study solely involved retrospective review of
medical records.
Study Variables and Definitions
Variables collected from the electronic health
record included demographics, comorbid con-
ditions [Charlson score and quick sequential
organ failure assessment (qSOFA) score], and
pharmacologic information, including time to
initiation of antifungal therapy, type of anti-
fungal therapy, antifungal dosing, antifungal
frequency, and antifungal duration of therapy.
Microbiology and infectious-related
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information, including source of infection,
species isolated, presence of infectious diseases
consultation, and presence and timing of source
control were assessed. Additional data collected
included infection-related length of stay (time
from the first positive Candida blood culture
until the day of hospital discharge), total hos-
pital length of stay, in-hospital mortality,
30-day readmission, clinical failure, and whe-
ther the infection was healthcare associated
(fungemia developed[48 h after hospital
admission). Obesity was defined according to
the Centers for Disease Control and Prevention
as a body mass index (BMI) C 30 kg/m2 [12].
Clinical failure was defined as persistently pos-
itive fungemia (C 7 days) or development/per-
sistence of multi-organ failure or persistently
positive/increasing 1,3-beta-D-glucan concen-
trations plus at least one of the following:
WBC[12,000 cells/mm3 or\4000 cells/mm3
or temperature[38 C or\ 35 C.
Clinical Outcomes
The primary outcome was infection-related
length of stay between the obese and non-obese
patient populations. Secondary endpoints
included the difference in time to candidemia
resolution, 30-day readmission rates, and in-
hospital mortality.
Data Analysis
For comparisons between the obese and non-
obese groups, categorical data were analyzed
utilizing Pearson’s chi-square or Fisher’s exact
test, as appropriate, and continuous data were
analyzed utilizing the Mann-Whitney U test or
Student’s t test, as appropriate. A two-sided
P value of 0.05 was considered statistically sig-
nificant. Statistical analyses were performed
using SPSS (version 24.0, IBM, Armonk, NY).
RESULTS
The cohort included 80 unique patients, with
28 patients in the obese group and 52 patients
in the non-obese group. Patient characteristics
are listed in Table 1. The majority of patients
were male (55%) with a median [interquartile
range] age of 53.5 [39–63] years. Baseline char-
acteristics were comparable between the groups
with the exception of weight, BMI, and pres-
ence of hypertension. The median BMI and
weight were 36.3 [31.7–41.3] kg/m2 and 102.5
[91.2–111.1] kg versus 20.4 [17.3–25.8] kg/m2
and 61.4 [50.8–72.6] kg in the obese and non-
obese groups, respectively (p\0.01). The most
commonly isolated Candida species were C.
albicans (37.5%) followed by C. glabrata (30%)
with no differences observed between either
group. Only two cultures with C. krusei were
isolated: one in each group. Only four isolates
were identified that were fluconazole resistant
or susceptible dose-dependent, with two occur-
ring in each group of patients. Fifty-eight (73%)
patients received micafungin, 21 (26%) patients
received fluconazole, and 1 (1%) patient
received posaconazole. While there were no
differences between groups regarding treatment
selection, 16 (31%) non-obese patients com-
pared with 5 (18%) obese patients received flu-
conazole (p = 0.211), and 36 (69%) non-obese
patients compared with 22 (79%) obese patients
received micafungin (p = 0.372). The mica-
fungin dosage used in all patients was 100 mg
daily whereas the fluconazole dose was 400 mg
daily, which was adjusted for those with renal
impairment.
The primary outcome of infection-related
length of stay was 19 [10–42] days in the obese
patients and 13 [8–19] days in the non-obese
patients (p = 0.05) (Table 2). Micafungin was
the most commonly utilized empiric antifungal
(obese: 78.6% vs. non-obese: 69.2%). However,
obese patients remained on micafungin for
definitive therapy more frequently than non-
obese patients (57.1% vs. 21.2%; p\0.01).
Additionally, obese patients were treated with
definitive therapy longer than non-obese
patients at 13 [10–16] days versus 10 [5–14] days
(p = 0.04). Definitive therapy was initiated fas-
ter in obese patients: 13 [4–44] h vs. 51 [3–11] h
(p = 0.03). There were no differences in fre-
quency (p = 0.15) or timing of source control
(p = 0.88), which occurred in 33.8% of patients
at a median of 30 [12–72] h among obese and
non-obese patients. However, 82.1% of obese
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Table 1 Patient demographics
Variable presented as # (%) or median
(IQR)
Total (n = 80) Obese (n = 28) Non-obese
(n = 52)
p value
Age (years) 53.5 [39–63] 59 [39.5–65] 49.5 [37.25–60.75] 0.13
Sex, male 44 (55) 11 (39.3) 33 (63.5) 0.04
Race
Caucasian 32 (40) 10 (35.7) 22 (42.3) 0.57
African American 45 (56.3) 17 (60.7) 28 (53.8) 0.56
Hispanic 1 (1.3) 1 (3.6) 0 (0) 0.35
Other, Indian 1 (1.3) 0 (0) 1 (1.9) 1.00






BMI 25.9 [19.0125–33] 36.3 [31.65–41.275] 20.42
[17–25.7975]
\0.001





Baseline temperature, C 37.2 [36.7–38.675] 37.15
[36.625–39.025]
37.4 [36.705–38.6] 0.68









Respiratory rate[ 22 28 (35) 12 (42.9) 16 (30.8) 0.28
GCS\ 13 15 (18.8) 7 (25) 8 (15.4) 0.29
SBP\ 100 38 (47.5) 12 (42.9) 26 (50) 0.54
qSOFA score 1 [0–2] 1 [0–2] 1 [0–2] 0.60
Hypertension 48 (60) 21 (75) 27 (51.9) 0.04
Neutropenic 11 (13.8) 3 (10.7) 8 (15.4) 0.74
VTE 17 (21.3) 6 (21.4) 11 (21.2) 0.98
Nutrition
Enteral tube feeds 16 (20) 4 (14.3) 12 (23.1) 0.35
Parenteral 28 (35) 13 (46.4) 15 (28.8) 0.12
Solid/liquid food 36 (45) 11 (39.3) 25 (48.1) 0.45
Previous antifungal use 12 (15) 7 (25) 5 (9.6) 0.10
Systemic corticosteroids 8 (10) 5 (17.9) 3 (5.8) 0.12
Charlson 3 [1–5] 3 [1–4.75] 3 [1–5] 0.72
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Table 1 continued
Variable presented as # (%) or median
(IQR)




36.1–38.9 65 (81.3) 21 (75) 44 (84.6) 0.29
35.1–36 or 39–39.9 13 (16.3) 5 (17.9) 8 (15.4) 0.76
B 35 or C 40 2 (2.5) 2 (7.1) 0 (0) 0.12
Hypotension 24 (30) 5 (17.9) 19 (36.5) 0.08
Mechanical ventilation 17 (21.3) 6 (21.4) 11 (21.2) 0.98
Pitt bacteremia score 1 [0–3] 1 [0–2.75] 1 [0–3] 0.50
Suspected/documented source of infection
CVC 8 (10) 4 (14.3) 4 (7.7) 0.44
Urine 6 (7.5) 1 (3.6) 5 (9.6) 0.66
GI tract 11 (13.8) 5 (17.9) 6 (11.5) 0.50
Other 4 (5) 0 (0) 4 (7.7) 0.29
Unknown 27 (33.8) 12 (42.9) 15 (28.8) 0.21
Healthcare-associated 53 (66.3) 19 (67.9) 34 (65.4) 0.82
Source control 27 (33.8) 8 (28.6) 19 (36.5) 0.47
BMI body mass index, SCr serum creatinine, C Celsius, GCS Glascow Coma Score, SBP systolic blood pressure, qSOFA
quick sequential organ failure assessment, VTE venous thromboembolism, CVC central venous catheter, GI gastrointestinal
Table 2 Clinical outcomes
Variable presented as # (%) or median (IQR) Total (n = 80) Obese (n = 28) Non-obese (n = 52) p value
Infection-related length of stay (days) 13 [9–24] 19 [10–42] 13 [8–19] 0.05
Duration of candidemia (days) 5 [4–7] 6 [4–9] 5 [3–6] 0.02
30-Day readmission disposition (n = 67) N = 22 N = 45
Alive, not readmitted 53 (79.1) 19 (86.4) 34 (75.6) 0.36
Alive, infection-related readmission 3 (4.5) 0 (0) 3 (6.7) 0.55
Alive, non-infection-related readmission 6 (9) 2 (9.1) 4 (8.9) 1.00
Dead 4 (6) 0 (0) 4 (8.9) 0.29
Unknown 1 (1.5) 1 (4.5) 0 (0) 0.33
In-hospital mortality 13 (16.3) 6 (21.4) 7 (13.5) 0.36
Infect Dis Ther (2020) 9:175–183 179
patients compared with 55.8% non-obese
patients received infectious diseases consulta-
tion (p = 0.02).
In-hospital mortality was numerically higher
in obese patients versus non-obese patients with
observed rates of 21.4% vs. 13.5% (p = 0.36).
Clinical failure was comparable between both
groups with rates of 64.3% and 75% in the
obese and non-obese patients (p = 0.31). In
subgroup analyses aimed at identifying risk
factors for clinical failure, baseline WBC
(p\ 0.01), baseline respiratory rate[22 breaths
per minute (p = 0.01), baseline temperature
(p\ 0.01), hematologic malignancy (p = 0.03),
and mechanical ventilation (p = 0.02) were
identified.
DISCUSSION
To our knowledge, this is the first report that
evaluates the impact of obesity on outcomes
associated with Candida bloodstream infections.
Similar to reported trends in Candida epidemi-
ology, the predominantly identified pathogens
in this study were C. albicans and C. glabrata
[13–15]. Obese patients had slightly more C.
glabrata, but this number was not significant.
Obesity did not impact the choice of empiric
antifungal therapy, although numerically more
obese patients were treated with echinocandins.
However, significantly more obese patients
received an echinocandin as definitive therapy.
This may be explained by the higher proportion
of patients in this group with C. glabrata, the
almost 10% less source control in the obese
group, or the higher number of infectious dis-
eases consults in the obese group.
The results of this study are comparable to
published literature on overall outcomes asso-
ciated with candidemia. First, in this study, the
infection-related length of stay was a median of
13 days, which is similar to a study conducted
among patients in internal medicine wards [16].
Obese patients had an infection-related length
of stay roughly 7 days longer than non-obese
patients. Next, the duration of candidemia in
this study was a median of 5 days, which is
shorter than the 10 days reported in patients in
an intensive care unit [17]. However, obese
patients had a significantly longer duration of
candidemia, which may be responsible for the
longer length of stay. Finally, the overall in-
hospital mortality rate was 16.3%, which is
lower than the 83% reported in intensive care
units, but falls within the range of 5–71% that
has been reported otherwise [17, 18]. Although
there was no statistical difference in mortality
between groups, one may argue that a 7% dif-
ference in mortality may be clinically relevant.
General risk factors for candidemia have
been established, but limited information is
available related to risk factors for clinical fail-
ure [16, 19]. Compared with general reports of
successful treatment in 70% of patients, our
rates of clinical failure of 65–75% are high [20].
This is likely due to discrepancies in definitions
of success and failure between studies.
Although limited information is available on
the impact of obesity in candidemia, several
studies have been published related to the effect
of obesity in other infectious diseases with
mixed results [21–23]. In one study, obesity was
associated with decreased 30-day mortality in
pneumonia, but had no impact on mortality in
urinary tract infections, skin infections, or
bloodstream infections [21]. No differences in
length of stay or requirement for intensive care
were found between obese and non-obese
groups. In a second study, higher BMI was
associated with increased risk of all-cause mor-
tality and organ failure in patients with gram-
negative bloodstream infections [22]. Finally, in
obese patients with sepsis, all-cause mortality
was lower, length of stay was longer, and hos-
pital costs were higher than in non-obese
patients [23]. Taken together, these results lend
support to the findings of increased mortality
and length of stay in obese patients with Can-
dida bloodstream infections that were found in
this study.
This study is not without limitations. First,
this study was retrospective, which is prone to
selection bias and confounding variables. In
this trial, all patients who met inclusion criteria
during this period were included, limiting
selection bias. In addition, standard definitions
were used, and these were applied consistently
between obese and non-obese groups. Demo-
graphics, comorbidity scores, and severity of
180 Infect Dis Ther (2020) 9:175–183
illness scores were compared between groups
and found to be similar, which should limit
confounding variables. Next, this study was
small and performed at a single center, which
may limit the generalizability of these results to
other centers or those with a different Candida
epidemiology or patient case mix. However, the
included patients were representative of obese
populations, those found at academic medical
centers, and those with Candida bloodstream
infections.
CONCLUSION
In conclusion, obese patients had a longer
infection-related length of stay, duration of
candidemia, and numerically higher in-hospital
mortality than non-obese patients. In addition,
obese patients were more likely to receive
echinocandins and to have infectious diseases
consults than non-obese patients. In the total
population, risk factors for clinical failure in
patients with Candida bloodstream infection
were hematologic malignancy, presence of
mechanical ventilation, and baseline WBC,
respiratory rate, and temperature. Information
from larger cohorts would be beneficial to fur-
ther delineate the impact of obesity and the
specific risk factors for clinical failure in patients
with Candida bloodstream infections.
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